253 related articles for article (PubMed ID: 15486204)
1. Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin.
Kasparkova J; Fojta M; Farrell N; Brabec V
Nucleic Acids Res; 2004; 32(18):5546-52. PubMed ID: 15486204
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of nuclear factor kappaB proteins-platinated DNA interactions correlates with cytotoxic effectiveness of the platinum complexes.
Brabec V; Kasparkova J; Kostrhunova H; Farrell NP
Sci Rep; 2016 Aug; 6():28474. PubMed ID: 27574114
[TBL] [Abstract][Full Text] [Related]
3. DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent.
Brabec V; Kaspárková J; Vrána O; Nováková O; Cox JW; Qu Y; Farrell N
Biochemistry; 1999 May; 38(21):6781-90. PubMed ID: 10346899
[TBL] [Abstract][Full Text] [Related]
4. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F
Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909
[TBL] [Abstract][Full Text] [Related]
5. Cellular pharmacology of polynuclear platinum anti-cancer agents.
Roberts JD; Peroutka J; Farrell N
J Inorg Biochem; 1999 Oct; 77(1-2):51-7. PubMed ID: 10626354
[TBL] [Abstract][Full Text] [Related]
6. Different recognition of DNA modified by aatitumor cisplatin and its clinically ineffective trans isomer by tumor suppressor protein p53.
Kasparkova J; Pospisilova S; Brabec V
J Biol Chem; 2001 May; 276(19):16064-9. PubMed ID: 11279186
[TBL] [Abstract][Full Text] [Related]
7. Energetics, conformation, and recognition of DNA duplexes containing a major adduct of an anticancer azolato-bridged dinuclear Pt(II) complex.
Mlcouskova J; Malina J; Novohradsky V; Kasparkova J; Komeda S; Brabec V
Biochim Biophys Acta; 2012 Oct; 1820(10):1502-11. PubMed ID: 22683702
[TBL] [Abstract][Full Text] [Related]
8. Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair of DNA intrastrand cross-links of novel antitumor trinuclear platinum complex BBR3464.
Zehnulova J; Kasparkova J; Farrell N; Brabec V
J Biol Chem; 2001 Jun; 276(25):22191-9. PubMed ID: 11303029
[TBL] [Abstract][Full Text] [Related]
9. Differences in the cellular response and signaling pathways of cisplatin and BBR3464 ([[trans-PtCl(NH3)(2)]2mu-(trans-Pt(NH3)(2)(H2N(CH2)(6)-NH2)2)]4+) influenced by copper homeostasis.
Kabolizadeh P; Ryan J; Farrell N
Biochem Pharmacol; 2007 May; 73(9):1270-9. PubMed ID: 17234160
[TBL] [Abstract][Full Text] [Related]
10. The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin.
Servidei T; Ferlini C; Riccardi A; Meco D; Scambia G; Segni G; Manzotti C; Riccardi R
Eur J Cancer; 2001 May; 37(7):930-8. PubMed ID: 11313183
[TBL] [Abstract][Full Text] [Related]
11. Monofunctional platinum-DNA adducts are strong inhibitors of transcription and substrates for nucleotide excision repair in live mammalian cells.
Zhu G; Myint M; Ang WH; Song L; Lippard SJ
Cancer Res; 2012 Feb; 72(3):790-800. PubMed ID: 22180496
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and activity of three new trinuclear platinums with cis-geometry for terminal metal centres.
Hamad SA; Beale P; Yu JQ; Huq F
J Biomed Sci; 2014 May; 21(1):41. PubMed ID: 24884683
[TBL] [Abstract][Full Text] [Related]
13. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
O'Neill CF; Hunakova L; Kelland LR
Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
[TBL] [Abstract][Full Text] [Related]
14. DNA compaction by mononuclear platinum cancer drug cisplatin and the trisplatinum anticancer agent BBR3464: Differences and similarities.
Banerjee T; Dubey P; Mukhopadhyay R
Biochimie; 2012 Feb; 94(2):494-502. PubMed ID: 21893159
[TBL] [Abstract][Full Text] [Related]
15. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin.
Fokkema E; Groen HJ; Helder MN; de Vries EG; Meijer C
Biochem Pharmacol; 2002 Jun; 63(11):1989-96. PubMed ID: 12093475
[TBL] [Abstract][Full Text] [Related]
16. Comparison of cytotoxicity and cellular accumulation of polynuclear platinum complexes in L1210 murine leukemia cell lines.
Roberts JD; Peroutka J; Beggiolin G; Manzotti C; Piazzoni L; Farrell N
J Inorg Biochem; 1999 Oct; 77(1-2):47-50. PubMed ID: 10626353
[TBL] [Abstract][Full Text] [Related]
17. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
[TBL] [Abstract][Full Text] [Related]
18. Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line.
Pestell KE; Hobbs SM; Titley JC; Kelland LR; Walton MI
Mol Pharmacol; 2000 Mar; 57(3):503-11. PubMed ID: 10692490
[TBL] [Abstract][Full Text] [Related]
19. Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs.
Brabec V; Kasparkova J
Drug Resist Updat; 2005 Jun; 8(3):131-46. PubMed ID: 15894512
[TBL] [Abstract][Full Text] [Related]
20. Cooperative effects in long-range 1,4 DNA-DNA interstrand cross-links formed by polynuclear platinum complexes: an unexpected syn orientation of adenine bases outside the binding sites.
Qu Y; Scarsdale NJ; Tran MC; Farrell NP
J Biol Inorg Chem; 2003 Jan; 8(1-2):19-28. PubMed ID: 12459895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
